Avid Radiopharmaceuticals, Inc. will speak at the 28th Annual JP Morgan Healthcare Conference on Wednesday, January 13, 2010. The conference will run from January 11-14 at The Westin St. Francis in San Francisco, California. Speaking for the company will be its Founder and CEO Daniel Skovronsky, M.D., Ph.D.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Dr. Skovronsky is scheduled to begin his presentation at 7:30 am PT in the Elizabethan C/D. He will provide an update of the company’s Phase III Clinical trials and its efforts to commercialize its amyloid imaging compound 18F-AV-45 (AV-45). For more information regarding the event, contact Avid Radiopharmaceuticals’ Chief Financial Officer Richard Baron at 215.298.0723, or by email at baron@avidrp.com.
Avid Radiopharmaceuticals, Inc. is a leader in the development of molecular imaging products with the potential for earlier and more effective detection, diagnosis, and monitoring of major chronic human diseases. Based in Philadelphia, Pa., the company is a pioneer in the development of molecular imaging agents for Alzheimer’s disease that could lead to earlier diagnosis and better evaluation of drugs designed to prevent or reverse amyloid plaque build-up in the brain. Avid is currently conducting Phase III clinical studies of 18F-AV-45 for imaging amyloid plaques in Alzheimer’s disease, and is in Phase I and II trials with 18F-AV-133 for imaging the vesicular monoamine transporter (VMAT2) in diseases involving dopaminergic degeneration (Parkinson’s disease and Dementia with Lewy Bodies) and beta cell dysfunction (Type I and Type II Diabetes Mellitus).
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
